392 related articles for article (PubMed ID: 15942579)
21. The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
Mineo TC; Ambrogi V; Pompeo E; Baldi A; Stella F; Aurea P; Marino M
Ann Thorac Surg; 2008 May; 85(5):1740-6. PubMed ID: 18442576
[TBL] [Abstract][Full Text] [Related]
22. Extrapleural pneumonectomy for primary pleural mullerian tumor in a young woman.
Farivar AS; Louie BE; Aye RW; Horton MP; Vallières E
Ann Thorac Surg; 2012 Jan; 93(1):e1-2. PubMed ID: 22186481
[TBL] [Abstract][Full Text] [Related]
23. Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging.
Steinert HC; Santos Dellea MM; Burger C; Stahel R
Lung Cancer; 2005 Jul; 49 Suppl 1():S33-5. PubMed ID: 15950798
[No Abstract] [Full Text] [Related]
24. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
Flores RM; Akhurst T; Gonen M; Larson SM; Rusch VW
J Thorac Cardiovasc Surg; 2003 Jul; 126(1):11-6. PubMed ID: 12878934
[TBL] [Abstract][Full Text] [Related]
25. [Extrapleural pneumonectomy for malignant pleural mesothelioma].
Morohoshi T; Yamamoto T; Nagashima T
Kyobu Geka; 2007 Jan; 60(1):40-4. PubMed ID: 17249537
[TBL] [Abstract][Full Text] [Related]
26. Imaging, staging and response evaluation.
Byrne M; Hillerdal G
Lung Cancer; 2005 Jul; 49 Suppl 1():S25-6. PubMed ID: 15950795
[No Abstract] [Full Text] [Related]
27. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results.
Nomori H; Mori T; Ikeda K; Kawanaka K; Shiraishi S; Katahira K; Yamashita Y
J Thorac Cardiovasc Surg; 2008 Apr; 135(4):816-22. PubMed ID: 18374761
[TBL] [Abstract][Full Text] [Related]
28. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.
Orki A; Akin O; Tasci AE; Ciftci H; Urek S; Falay O; Kutlu CA
Thorac Cardiovasc Surg; 2009 Jun; 57(4):217-21. PubMed ID: 19670115
[TBL] [Abstract][Full Text] [Related]
29. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
Neragi-Miandoab S; Richards WG; Sugarbaker DJ
Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
[TBL] [Abstract][Full Text] [Related]
30. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
Tilleman TR; Richards WG; Zellos L; Johnson BE; Jaklitsch MT; Mueller J; Yeap BY; Mujoomdar AA; Ducko CT; Bueno R; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2009 Aug; 138(2):405-11. PubMed ID: 19619785
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer.
Meyers BF; Haddad F; Siegel BA; Zoole JB; Battafarano RJ; Veeramachaneni N; Cooper JD; Patterson GA
J Thorac Cardiovasc Surg; 2006 Apr; 131(4):822-9; discussion 822-9. PubMed ID: 16580440
[TBL] [Abstract][Full Text] [Related]
32. The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
Edwards JG; Stewart DJ; Martin-Ucar A; Muller S; Richards C; Waller DA
J Thorac Cardiovasc Surg; 2006 May; 131(5):981-7. PubMed ID: 16678579
[TBL] [Abstract][Full Text] [Related]
33. Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy.
Allen KB; Faber LP; Warren WH
Chest Surg Clin N Am; 1994 Feb; 4(1):113-26. PubMed ID: 8055276
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
Zellos L; Richards WG; Capalbo L; Jaklitsch MT; Chirieac LR; Johnson BE; Bueno R; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2009 Feb; 137(2):453-8. PubMed ID: 19185169
[TBL] [Abstract][Full Text] [Related]
35. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Wang ZJ; Reddy GP; Gotway MB; Higgins CB; Jablons DM; Ramaswamy M; Hawkins RA; Webb WR
Radiographics; 2004; 24(1):105-19. PubMed ID: 14730040
[TBL] [Abstract][Full Text] [Related]
36. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
de Perrot M; Uy K; Anraku M; Tsao MS; Darling G; Waddell TK; Pierre AF; Bezjak A; Keshavjee S; Johnston MR
J Thorac Cardiovasc Surg; 2007 Jan; 133(1):111-6. PubMed ID: 17198794
[TBL] [Abstract][Full Text] [Related]
37. Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
Yan TD; Boyer M; Tin MM; Sim J; Kennedy C; McLean J; Bannon PG; McCaughan BC
Ann Thorac Surg; 2009 May; 87(5):1552-6. PubMed ID: 19379903
[TBL] [Abstract][Full Text] [Related]
38. Is positron emission tomography useful in locoregional staging of esophageal cancer? Results of a multidisciplinary initiative comparing CT, positron emission tomography, and EUS.
Sandha GS; Severin D; Postema E; McEwan A; Stewart K
Gastrointest Endosc; 2008 Mar; 67(3):402-9. PubMed ID: 18178202
[TBL] [Abstract][Full Text] [Related]
39. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability.
Patz EF; Shaffer K; Piwnica-Worms DR; Jochelson M; Sarin M; Sugarbaker DJ; Pugatch RD
AJR Am J Roentgenol; 1992 Nov; 159(5):961-6. PubMed ID: 1414807
[TBL] [Abstract][Full Text] [Related]
40. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
Sterman DH; Albelda SM
Respirology; 2005 Jun; 10(3):266-83. PubMed ID: 15955137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
